23andMe finds a buy­er for its IL-36 bis­pe­cif­ic in Almi­rall; Neu­ro­crine, Idor­sia re­vise epilep­sy drug deal

→ The first fruits of 23andMe’s ef­forts to gen­er­ate new drugs off the in­sights it gained from a mas­sive amount of ge­net­ic da­ta are tak­ing shape, and Almi­rall is sign­ing up to ripen one of them. The Span­ish der­ma­tol­ogy drug­mak­er has li­censed a bis­pe­cif­ic an­ti­body that blocks three cy­tokines in the IL-36 cy­tokine fam­i­ly, which are tied to skin con­di­tions such as pso­ri­a­sis and lu­pus, in ad­di­tion to oth­er in­flam­ma­to­ry ail­ments such as ul­cer­a­tive col­i­tis, in­flam­ma­to­ry bow­el dis­ease, and Crohn’s dis­ease.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN